-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Omicron variant of SARS-CoV-2 causes less severe disease than the Delta virus, although it evades immune protection more easily through vaccination and previous infection
A new study by a research team of scientists from the Universities of Kent and Goethe University Frankfurt shows that Omicron variant viruses are particularly sensitive to inhibition of the so-called interferon response, a non-specific immune response
Cell culture studies also showed that Omicron virus remains sensitive to the eight most important antiviral drugs and drug candidates for the treatment of COVID-19
EIDD-1931 (active metabolite of molnupiravir), ribavirin, remdesivir, favipravir, rf-07321332 (nirmatrelvir, active ingredient of paxlovid), nafamostat, camostat, and aprotinin
Professor Martin Michaelis, from the University of Kent's School of Biological Sciences, said: "Our study explains for the first time why Omicron infection is unlikely to lead to severe disease
Professor Jindrich Cinatl from the Institute of Medical Virology at Goethe University added: "While cell culture experiments do not accurately reflect the more complex situation in patients, our data provide encouraging evidence that existing antiviral COVID-19 drugs Also works on Omicron
article title
Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates
